MedTrace Logo

Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma

NCT00165217 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2007-12-21

No results posted yet for this study

Summary

The purpose of this study is to collect information about the antitumor activity and the safety of capecitabine and thalidomide in patients with colorectal cancer.

Conditions

  • Colorectal Adenocarcinoma

Interventions

DRUG

Capecitabine

DRUG

Thalidomide

Sponsors & Collaborators

Principal Investigators

  • Charles S. Fuchs, MD, MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165217 on ClinicalTrials.gov